BridgeBio Pharma BBIO
NASDAQ BBIO
$67.79 +0.24 (+0.36%)
As of: Oct 21, 2026 · 10:14 AM EDT

BridgeBio Pharma (BBIO) Convertible Debt (2021 - 2022)

Updated

BridgeBio Pharma's Convertible Debt was $1.28 billion in Q3 2022, up 0.1% from the prior quarter.

Analysis

BridgeBio Pharma (BBIO) Convertible Debt (2021 - 2022) Analysis & Trends

At the end of FY2021, Convertible Debt at BridgeBio Pharma came in at $1.27 billion.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.97 Bn 1,099.55 Bn 19.71 Bn
2 Johnson & Johnson 614.97 Bn 533.50 Bn 17.26 Bn
3 AbbVie 505.56 Bn 478.67 Bn 12.70 Bn
4 Merck 366.86 Bn 321.23 Bn 12.21 Bn
5 Novartis Ag 297.80 Bn 261.79 Bn 11.24 Bn
6 Astrazeneca 261.62 Bn 235.31 Bn 12.86 Bn
7 Amgen 235.78 Bn 191.18 Bn 7.24 Bn
8 Gilead Sciences 189.91 Bn 164.11 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 BridgeBio Pharma 13.28 Bn 10.39 Bn 228.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 1.28 Bn
Jun 30, 2022 1.27 Bn
Dec 31, 2021 1.27 Bn
API Access

BridgeBio Pharma Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=BBIO&period=max&api_key=YOUR_API_KEY